Date: 3 March 2010
Background
Until now, BEIJING SEKISUI TRANK MEDICAL TECHNOLOGY CO., LTD. (hereinafter Sekisui Trank) has handled business development in China in the area of vacuum blood collection tubes, and SHANGHAI DAIICHI DIAGNOSTICS, CO., LTD. (hereinafter Shanghai Daiichi) has handled business development in China in the area of clinical reagents.
Sekisui Trank, established as a joint venture with a Chinese firm, manufactures and sells vacuum blood collection tubes. In addition to its plant in Beijing, it also has sales facilities located across China, and it is achieving steady sales growth including exports to Asian markets.
Shanghai Daiichi provides support for the activities of sales agents in China for reagents exported by SEKISUI MEDICAL CO., LTD. (hereinafter Sekisui Medical). Against a background of a growing Chinese market for reagents, in recent years the value of exports has continued to increase from year to year.
2. Outline of this merger
With this merger, Shanghai Daiichi will be merged into Sekisui Trank, to form a major facility in the Chinese market. Plans call for the merger procedures to be completed in September of this year.
Also, plans call for the Sekisui Trank plant that currently produces vacuum blood collection tubes to begin production of clinical reagents as well following the merger.
Also, in advance of this merger Sekisui Chemical accepted transfer in December of last year of a 15% of equity stake held by a Chinese joint-venture partner of Sekisui Trank, increasing its stake in the company from 85% to 100%. Furthermore, in February of this year the name of Sekisui Trank was changed to SEKISUI MEDICAL TECHNOLOGY (CHINA) LTD., to develop a unified brand image and increase its presence in the medical industry in China.
Read more here.
Add new comment